Subscribe
shutterstock_1851383767_michael_vi
Michael Vi / Shutterstock.com
13 January 2022Big PharmaMuireann Bolger

Eli Lilly avoids sanctions in Teva migraine treatment dispute

Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.
Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
Americas
Teva can pursue migraine patent dispute against Eli Lilly
17 March 2022   Eli Lilly has failed to convince a US judge to toss a patent infringement lawsuit filed by Teva Pharmaceuticals in a dispute over a migraine medication.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.
Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
Americas
Teva can pursue migraine patent dispute against Eli Lilly
17 March 2022   Eli Lilly has failed to convince a US judge to toss a patent infringement lawsuit filed by Teva Pharmaceuticals in a dispute over a migraine medication.

More on this story

Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.
Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
Americas
Teva can pursue migraine patent dispute against Eli Lilly
17 March 2022   Eli Lilly has failed to convince a US judge to toss a patent infringement lawsuit filed by Teva Pharmaceuticals in a dispute over a migraine medication.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York